Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$24.85 +2.1%	$26.29	$14.80 ▼ $40.47	$1.89B	0.87	999,596 shs	669,886 shs
DNLI Denali Therapeutics	$13.96 -1.9%	$14.30	$10.57 ▼ $33.33	$2.03B	1.36	1.66 million shs	2.20 million shs
TRML Tourmaline Bio	$20.72 -2.9%	$18.71	$11.56 ▼ $29.79	$532.19M	2.04	199,916 shs	178,434 shs
VCEL Vericel	$36.24 +0.2%	$40.32	$33.09 ▼ $63.00	$1.83B	1.27	654,731 shs	449,982 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-5.55%	-8.34%	+4.68%	-19.99%
DNLI Denali Therapeutics	0.00%	+3.87%	-9.06%	-2.99%	-35.61%
TRML Tourmaline Bio	0.00%	-4.78%	+19.29%	+37.31%	+51.24%
VCEL Vericel	0.00%	+1.71%	-12.10%	-13.16%	-20.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGON CG Oncology	1.5988 of 5 stars	3.5	2.0	0.0	1.6	0.8	0.0
DNLI Denali Therapeutics	4.1997 of 5 stars	3.6	1.0	4.7	3.8	3.3	0.0
TRML Tourmaline Bio	1.8772 of 5 stars	3.5	0.0	0.0	3.1	2.5	0.0
VCEL Vericel	2.0648 of 5 stars	3.5	0.0	0.0	2.5	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	3.08	Buy	$55.30	122.54% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.85	142.45% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	138.10% Upside
VCEL Vericel	3.00	Buy	$60.33	66.48% Upside

Current Analyst Ratings Breakdown

Latest TRML, VCEL, CGON, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/16/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $53.00
7/10/2025	CGON CG Oncology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$40.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
6/16/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$1.14M	1,661.46	N/A	N/A	$9.63 per share	2.58
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	$8.53 per share	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A
VCEL Vericel	$237.22M	7.71	$0.31 per share	115.97	$6.08 per share	5.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$88.04M	-$1.51	N/A	N/A	N/A	-15,945.17%	-16.71%	-16.24%	8/14/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	N/A
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/14/2025 (Estimated)
VCEL Vericel	$10.36M	$0.12	302.03	82.36	N/A	2.85%	2.47%	1.69%	N/A

Latest TRML, VCEL, CGON, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TRML Tourmaline Bio	-$0.95	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	CGON CG Oncology	-$0.49	-$0.54	-$0.05	-$0.54	$0.11 million	N/A
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	30.97	30.97
DNLI Denali Therapeutics	N/A	9.56	9.56
TRML Tourmaline Bio	N/A	33.87	33.87
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
DNLI Denali Therapeutics	92.92%
TRML Tourmaline Bio	91.89%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	7.40%
DNLI Denali Therapeutics	12.50%
TRML Tourmaline Bio	13.00%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	76.22 million	70.58 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable
VCEL Vericel	300	50.46 million	47.84 million	Optionable

TRML, VCEL, CGON, and DNLI Headlines

Recent News About These Companies

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9 at 5:54 AM | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8 at 3:20 AM | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Up 308.4% in July

August 5, 2025 | americanbankingnews.com

Vericel FY2025 EPS Forecast Decreased by Leerink Partnrs

August 5, 2025 | americanbankingnews.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

Canaccord Genuity Group Cuts Vericel (NASDAQ:VCEL) Price Target to $58.00

August 4, 2025 | americanbankingnews.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Update

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Sold by Baker Avenue Asset Management LP

August 3, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Price Target Cut to $58.00 by Analysts at Canaccord Genuity Group

August 2, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Hits New 52-Week Low - Here's What Happened

August 2, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Q2 2025 Earnings Call Transcript

August 2, 2025 | msn.com

Vericel Corporation Reports Strong Q2 2025 Earnings

August 1, 2025 | tipranks.com

Vericel (NASDAQ:VCEL) Shares Gap Down - Here's What Happened

August 1, 2025 | marketbeat.com

Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result

August 1, 2025 | finance.yahoo.com

Vericel Corporation (VCEL) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

Vericel Corporation Reports Strong Q2 2025 Results

July 31, 2025 | tipranks.com

Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

July 31, 2025 | zacks.com

Vericel Reports Second Quarter 2025 Financial Results

July 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRML, VCEL, CGON, and DNLI Company Descriptions

CG Oncology NASDAQ:CGON

$24.85 +0.50 (+2.05%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$24.84 -0.02 (-0.06%)

As of 08/8/2025 05:46 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Denali Therapeutics NASDAQ:DNLI

$13.96 -0.27 (-1.90%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$13.88 -0.08 (-0.54%)

As of 08/8/2025 07:35 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Tourmaline Bio NASDAQ:TRML

$20.72 -0.61 (-2.86%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$20.71 -0.01 (-0.05%)

As of 08/8/2025 04:10 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Vericel NASDAQ:VCEL

$36.24 +0.09 (+0.25%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$36.24 -0.01 (-0.01%)

As of 08/8/2025 06:22 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time